Usa covid-19 infection patient Coronavirus Usa

Incyte begins Phase III trial of ruxolitinib to treat Covid-19

Reading now: 915
www.pharmaceutical-technology.com

Incyte has started a Phase III clinical trial of ruxolitinib (Jakafi) to treat cytokine storm caused by Covid-19 coronavirus infection.

Cytokine storm is an immune overreaction to a viral infection and can result in serious complications such as pneumonia and acute respiratory distress syndrome (ARDS).

Ruxolitinib is a JAK1/JAK2 inhibitor approved for polycythemia vera, myelofibrosis and graft-versus-host disease. The global, randomised, double-blind, placebo-controlled Phase III trial, named RUXCOVID, will assess the safety and efficacy of ruxolitinib given along with standard-of-care (SoC) in around 400 patients aged ≥12 years worldwide.

Read more on pharmaceutical-technology.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA